In patients with DM, platelet hyperactivity, in the presence of oxidative stress, have been found to increase the progression of thrombotic and cardiovascular events.[24] Therefore, a combination of DT with a NOAC and a P2Y12 inhibitor for the treatment of DM patients with AF postPCI might be included in future guidelines. This evidence concerns the gene P2RY12 and atrial fibrillation.